Exhibit 99.1 Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2022 and December 31, 2021 and for the Six Months Ended June 30, 2022 and 2021 | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income or Loss | 2 | | Condensed Consolidated Interim Statement of Financial Position | 3 | | Condense ...

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2021 Earnings Conference Call April 12, 2022 8:00 AM ET Company Participants Thomas Meyer - Chief Executive Officer Marcel Gremaud - Chief Financial Officer Conference Call Participants Operator Good morning and welcome to Altamira Therapeutics Conference Call. On today's call are Thomas Meyer, Altamira Therapeutics' Founder, Chairman and Chief Executive Officer; and Marcel Gremaud, Altamira Therapeutics' Chief Financial Officer, who will present the company's fin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, par value CHF 0.01 per share CYTO The Nasdaq Stock Market LLC FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT ...

Targeting important unmet medical needs Corporate Presentation September 2021 Forward-Looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' (formerly Auris Medical) strategies or expect ...

Company Presentation 2021 LD Micro Invitational XI – June 9, 2021 Forward-looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In s ...

Financial Performance - Net loss for H2 2020 was CHF 5.5 million, or CHF 0.75 per share, compared to CHF 3.0 million, or CHF 0.83 per share, for H2 2019[14]. - Net loss attributable to owners for 2020 was CHF 8.2 million, or CHF 1.36 per share, compared to CHF 6.6 million, or CHF 2.28 per share, for 2019[18]. - Net loss attributable to owners of the Company for the twelve months ended December 31, 2020, was CHF 8,200,165, compared to CHF 6,631,901 in 2019, indicating an increase of approximately 23.7%[26]. - Basic and diluted loss per share for the twelve months ended December 31, 2020, was CHF (1.36), compared to CHF (2.28) in 2019, showing an improvement of approximately 40.4%[26]. Operating Expenses - Total operating expenses for H2 2020 were CHF 2.9 million, a decrease from CHF 3.2 million in H2 2019[13]. - Total operating expenses for 2020 were CHF 5.3 million, down from CHF 7.3 million in 2019[16]. - Total operating loss for the six months ended December 31, 2020, was CHF 2,862,459, a decrease from CHF 3,151,586 in the same period of 2019, representing a reduction of approximately 9%[26]. - Research and development expenses decreased to CHF 1,978,232 for the six months ended December 31, 2020, compared to CHF 2,020,990 in 2019, reflecting a decline of about 2%[26]. Cash and Assets - Cash and cash equivalents at December 31, 2020, totaled CHF 11.3 million[15]. - Cash and cash equivalents rose to CHF 11,258,870 in 2020, up from CHF 1,384,720 in 2019, representing an increase of approximately 713%[28]. - Total assets increased significantly to CHF 20,799,367 in 2020 from CHF 9,226,151 in 2019, marking an increase of about 125%[28]. Liabilities - Total liabilities increased to CHF 4,029,477 in 2020 from CHF 3,190,018 in 2019, reflecting an increase of about 26%[28]. Shareholder Information - Auris Medical raised CHF 16.6 million in equity through share placements and warrant exercises[11]. - The average weighted number of shares outstanding increased to 7,432,839 in the six months ended December 31, 2020, compared to 3,628,614 in the same period of 2019, an increase of approximately 105%[26]. Future Outlook - Auris Medical expects to launch AM-301 nasal spray in selected markets towards the end of Q2 2021[2]. - The Phase 2 trial for AM-125 in acute vertigo is expected to complete enrollment in Q3 2021[2]. - The company anticipates total cash needs in 2021 to be between CHF 11.5 to 13 million[21]. - A strategy review is ongoing to explore potential strategic alternatives to maximize shareholder value[12]. Other Financial Metrics - Interest income for the six months ended December 31, 2020, was CHF 258, a significant decrease from CHF 17,882 in 2019, indicating a decline of about 98.6%[26]. - The Company reported a foreign currency exchange loss of CHF 303,531 for the six months ended December 31, 2020, compared to a gain of CHF 44,548 in 2019[26].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, par value CHF 0.01 per share EARS The Nasdaq Stock Market LLC FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT ...

Corporate Presentation September 2020 NASDAQ: EARS | Contact: investors@aurismedical.com Innovative Treatments in Neurotology and CNS Disorders Forward-looking Statements This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financi ...

Auris Medical Holding Ltd. (EARS) Q2 2020 Earnings Conference Call September 17, 2020 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman, CEO & MD Elmar Schaerli - CFO Conference Call Participants Maxim Jacobs - Edison Investment Research Limited Operator Good morning, and welcome to Auris Medical's Conference Call. On today's call are Thomas Meyer, Auris Medical's Chairman and Chief Executive Officer; and Elmar Schaerli, Auris Medical's Chief Financial Officer, who will present the company's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ OR ☐ SHELL COMPANY REPORT ...